| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/02/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/03/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 04/03/2023 | 50.38% | Piper Sandler | → $2 | Assumes | → Neutral |
| 03/09/2023 | 125.56% | Citigroup | $2 → $3 | Maintains | Buy |
| 03/08/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 12/02/2022 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/04/2022 | 125.56% | BMO Capital | $4 → $3 | Maintains | Outperform |
| 08/18/2022 | 1027.82% | HC Wainwright & Co. | $7 → $15 | Maintains | Buy |
| 08/17/2022 | 50.38% | Piper Sandler | $1 → $2 | Maintains | Neutral |
| 06/09/2022 | 125.56% | BMO Capital | $7 → $3 | Maintains | Outperform |
| 06/09/2022 | -6.02% | B. Riley Securities | $4 → $1.25 | Maintains | Neutral |
| 06/09/2022 | -39.85% | Citigroup | $7 → $0.8 | Downgrades | Buy → Neutral |
| 06/08/2022 | 426.32% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
| 06/08/2022 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 03/23/2022 | 200.75% | B. Riley Securities | → $4 | Initiates Coverage On | → Neutral |
| 02/18/2021 | 727.07% | HC Wainwright & Co. | $8 → $11 | Maintains | Buy |
| 11/09/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 08/06/2020 | 501.5% | Citigroup | $7 → $8 | Maintains | Buy |
| 05/27/2020 | 351.13% | JP Morgan | $7 → $6 | Maintains | Overweight |
| 12/09/2019 | 501.5% | BMO Capital | $11 → $8 | Maintains | Outperform |
| 11/15/2019 | 275.94% | Cantor Fitzgerald | $7 → $5 | Maintains | Overweight |
| 09/26/2019 | 426.32% | JP Morgan | → $7 | Assumes | → Overweight |
| 08/27/2018 | 539.1% | Citigroup | → $8.5 | Initiates Coverage On | → Buy |
What is the target price for Rigel Pharmaceuticals (RIGL)?
The latest price target for Rigel Pharmaceuticals (NASDAQ: RIGL) was reported by HC Wainwright & Co. on August 2, 2023. The analyst firm set a price target for $15.00 expecting RIGL to rise to within 12 months (a possible 1027.82% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rigel Pharmaceuticals (RIGL)?
The latest analyst rating for Rigel Pharmaceuticals (NASDAQ: RIGL) was provided by HC Wainwright & Co., and Rigel Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Rigel Pharmaceuticals (RIGL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rigel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rigel Pharmaceuticals was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.
Is the Analyst Rating Rigel Pharmaceuticals (RIGL) correct?
While ratings are subjective and will change, the latest Rigel Pharmaceuticals (RIGL) rating was a reiterated with a price target of $0.00 to $15.00. The current price Rigel Pharmaceuticals (RIGL) is trading at is $1.33, which is within the analyst's predicted range.